Buy the Yellen Dip: This Hated Small Biotech Company Becomes a Buyout Candidate
Biotech firms are taking a lot of heat lately. Gilead Sciences, for example, is being dragged back before government entities to defend the pricing of a hepatitis C drug that not only saves more lives than anything that's come before it but does so more cheaply than previous alternatives (see your June issue for details). It works so well that people are breaking the door down to get it, which is straining our already strained (and broken) socialized medical programs.
What regulators and lawmakers seem to forget is that without profits to fund expensive clinical drug discovery and development, we'd be dropping like flies from diseases that have long been tossed in history's dustbin. Furthermore, without expectation of future returns, new drugs for diseases that could kill us will simply not appear.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Technology Profits Confidential
With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.